Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
ID: 352012Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352012

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)." This grant aims to support research that enhances the understanding of trained immunity, focusing on its mechanisms, biomarkers, and implications for immune system development, vaccine responses, and conditions such as autoimmunity and allergic diseases. The initiative is significant for advancing immunological research and public health, encouraging applications from a diverse range of eligible organizations, including higher education institutions and nonprofits. Interested applicants should note that the application deadline is June 5, 2024, with the funding opportunity closing on January 8, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-112-Full-Announcement.html
    PAR-24-112.html
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity to enhance the understanding of "trained immunity," which refers to a non-specific immune memory in innate immune cells. The Research Project Grant (R01) aims to support projects exploring mechanisms and biomarkers of trained immunity, focusing on its implications for immune system development, vaccine responses, and conditions like autoimmunity and allergic diseases. Applications must align with NIAID's mission and are encouraged from various eligible organizations, including higher education institutions and nonprofits. Key dates include an application due date on June 5, 2024, and an expiration date for the funding opportunity on January 8, 2027. The grants do not permit clinical trials and emphasize the submission of applications through digital platforms. Review criteria will assess the project's significance, innovation, approach, and expertise of the investigators. This initiative underscores NIH's commitment to advancing immunological research and public health through rigorous scientific inquiry.
    Similar Opportunities
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    NIAID Research Education Program (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for the Research Education Program (R25 Clinical Trial Not Allowed) aimed at enhancing workforce training in biomedical, behavioral, and clinical research. This program seeks to support educational activities that include skills development, hands-on research experiences, and targeted mentoring, particularly for institutions serving underrepresented groups. The initiative is crucial for strengthening the research workforce capacity in alignment with NIH's mission, with funding capped at $351,000 per year for a maximum of five years. Interested applicants must submit their proposals by October 9, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life" (MIEL) under grant number RFA-AI-24-029. This initiative aims to support basic and applied research focused on understanding how immunity to HIV can be developed and maintained in children from birth to under 12 years old, particularly through the study of prophylactic vaccinations and broadly neutralizing antibodies (bNAbs). The NIH plans to commit $3 million for FY 2025 to fund 3-4 awards, with individual budgets not exceeding $750,000 per year. Applications are due by October 10, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) grant. This funding opportunity aims to support multi-project research initiatives that focus on infectious, immunologic, and allergic diseases, requiring each application to include at least two synergistic research projects and an administrative core, all centered around a common theme. The initiative is crucial for advancing research in areas such as the biology and pathogenesis of infectious microbes, immune system mechanisms, and the development of vaccines and therapeutics. Interested applicants must submit their proposals electronically via Grants.gov by September 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding amount is not limited but should reflect the actual needs of the proposed projects.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use," aimed at advancing the understanding of the interplay between neuroimmune networks and the effects of HIV and substance use disorders (SUD). This R01 Clinical Trial Not Allowed grant seeks applications that explore neuroimmune interactions, therapeutic targets, and modulatory tools, with a focus on examining the molecular mechanisms and regulatory pathways influenced by substance use in relation to HIV pathogenesis. The opportunity is significant for addressing HIV-related neurological issues exacerbated by substance abuse, with a total funding of up to $2 million projected for FY 2025 to support up to six projects. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at exploring the role of inflammasomes in the context of HIV infection and substance use disorders. This R21 exploratory grant encourages research into the mechanisms of inflammasome activation and their association with neurocognitive disorders in individuals affected by HIV and substance use, with a focus on identifying molecular markers and potential therapeutic innovations. The total funding available is up to $2 million over two years, with applications opening on February 13, 2024, and a submission deadline of March 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.